ArticleOncology letters2015
Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Circulating tumor cells as a recurrence risk marker in glioma: a retrospective study.Translational cancer research · 2025Article
- Pioneering the Photoactive Relevance of Quinazolinone-Fullereropyrrolidine Nanohybrids To Address Chemotherapeutic Resistance in Cancer.ACS medicinal chemistry letters · 2024Article
- Novel insights into biomarkers of progression in Desmoid tumor.Frontiers in oncology · 2023Review
- Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.Bioscience reports · 2022Article
- Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models.Theranostics · 2021Article
- Cyclin A in nonfunctioning pituitary adenomas.Endocrine · 2020Article
- Reciprocal Role Of DNA Methylation And Sp1 Binding In Ki-67 Gene Transcription.Cancer management and research · 2019Article
- Article
- Effects of Reduced Graphene Oxides on Apoptosis and Cell Cycle of Glioblastoma Multiforme.International journal of molecular sciences · 2018Article
- Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to analyze the expression and mutation of Cyclin A and Ki-67 in gliomas, and determine their correlation with tumor progression. Tissue samples of 186 diagnosed glioma patients were examined immunohistochemically for Cyclin A and Ki-67 expression. Gene mutation analysis was performed on genomic DNA extracted from patient samples, using polymerase chain reaction amplification and sequencing. Cyclin A and Ki-67 expression were observed in the glioma and lymphatic metastasis tissues, and were analyzed using SPSS 14.0 statistical software. Of the total patients, 64 (34.41%) were Cyclin A-positive and 68 (36.56%) were Ki-67-positive. The expression of Cyclin A and Ki-67 in glioma was positively correlated with lymphatic metastasis. Statistically significant differences were observed in the mutation rate of Ki-67 (P<0.05), but not Cyclin A (P>0.05), between the gliomas and metastatic tumors. In conclusion, Cyclin A and Ki-67 are highly expressed in glioma tissues, and their expression and mutation are associated with the lymphatic metastasis of glioma in the brain. It may be concluded that Cyclin A and Ki-67 may be used as biomarkers to guide the diagnosis of glioma and evaluate the prognosis of affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.